


LEQVIO® — A SMALL INTERFERING RNA THERAPY THAT SELECTIVELY TARGETS THE LIVER TO REGULATE LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA

LEQVIO®
(inclisiran) injection
284 mg/1.5 mL


HOW IS LDL-C REGULATED?

Cholesterol circulates in plasma within lipoprotein particles.^{1,2} Uptake of these particles by the liver is one of several tightly coordinated processes that maintain cholesterol homeostasis.¹



HOW LEQVIO WORKS

RNA interference (RNAi) is a biological process that regulates gene expression by inhibiting translation of specifically targeted messenger RNA (mRNA) into proteins.⁴ Therapies such as small interfering RNAs (siRNAs) have been developed to mimic the body's process of RNAi.⁵ LEQVIO is an siRNA therapy that was assessed for its efficacy and safety as an LDL-C-lowering therapy.³



STUDIES HAVE SHOWN LEQVIO TO HAVE HIGH SELECTIVITY FOR THE LIVER WITH REDUCED UPTAKE IN OTHER ORGANS⁴

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included angioedema. Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please see accompanying LEQVIO full Prescribing Information.

1. Trapani L et al. *World J Hepatol.* 2012;4(6):184-190. 2. Shapiro MD et al. *Circ Res.* 2018;122(10):1420-1438. 3. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 4. Ray KK et al. *N Engl J Med.* 2020;382(16):1507-1519. 5. Khvorova A. *N Engl J Med.* 2017;376(1):4-7.